MTNB חוב כולל להון Matinas BioPharma Holdings

Matinas BioPharma (MTNB) is scaling laboratory expenditures during the anti-infective agent testing phase while strictly adhering to environmental regulations and research ethics. This chart reflects a market price that captures the total debt-to-equity ratio at 0.01. The business relies on innovative proprietary LNC technology, developing advanced drug delivery systems in collaboration with leading industry partners.

This ratio serves as a critical filter during asset stress testing, measuring the proportion of debt relative to equity to assess financial stability. By analyzing the shift in the debt-to-equity ratio, an investor can identify the risks associated with Matinas BioPharma (MTNB), where a lack of revenue during the clinical trial stage leaves the company dependent on external financing to cover rising laboratory costs.